

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/183052 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) C12N 9/40 (2006.01)
A61K 48/00 (2006.01) C12N 15/52 (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:

PCT/US2022/017998

(22) International Filing Date:

25 February 2022 (25.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/154,485 26 February 2021 (26.02.2021) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1 Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors: **ISLAM, Rizwana**; 7 Simonds Road, Winchester, MA 01890 (US). **DESHPANDE, Mugdha, Ravindra**; 25 Pine Street, Arlington, MA 02474 (US). **NATARAJAN, Madhusudan**; 202 Winslow Road, Waban, MA 02468 (US). **PARK, Yung, Hee**; 5 Mayflower Road, Arlington, MA 02476 (US). **CHOI, Vivian**; c/o Takeda Pharmaceutical Company Limited, 125 Binney Street, 2.200-02, Cambridge, MA 02142 (US).

(74) Agent: **KIM, Sang-A** et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITION AND METHODS FOR THE TREATMENT OF FABRY DISEASE




FIG. 1

(57) Abstract: The present disclosure provides, among other things, a method of treating Fabry disease in a subject, the method comprising administering to a subject in need thereof a recombinant adeno-associated viral vector (rAAV) packaged in AAV capsid having broad tissue tropism, the vector comprising: (a) a 5' inverted terminal repeat; (b) a ubiquitous promoter; (c) a nucleotide sequence encoding wild-type α -GAL enzyme or a variant thereof; (d) optionally a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE); (e) a poly A; and (f) a 3' ITR.